SMARCB1:

Zhiying Wang1, Zhixian Zhong2, Yi Zhong3

  • 1Department of Oncology I, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Frontiers in oncology
|March 21, 2025
PubMed
概括

本病例报告详细介绍了第一个确定的SMARCB1/INI1缺陷差异化丸癌,一种高度侵袭性的恶性瘤. 瘤对传统治疗产生了耐药性,突出显示了需要新的治疗策略和与精子细胞癌的诊断差异化的需要.